ACCESS Newswire
CineBlock Launches Entertainment Investment Marketplace, Opening Film and Media Ownership to Everyday Fans
📈
AI Sentiment
Highly Positive
9/10
- Home
- VANI
as of 01-16-2026 3:38pm EST
$1.28
+$0.02
+1.23%
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 91.9M | IPO Year: | 2014 |
| Target Price: | $4.00 | AVG Volume (30 days): | 178.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.91 - $1.92 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered VANI Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vivani Medical Inc. (DE) (VANI)
Mendelsohn Aaron
Buy
Director
VANI Dec 29, 2025
Avg Cost/Share
$1.23
Shares
20,000
Total Value
$24,600.00
Owned After
188,170
SEC Form 4
Williams Gregg
Buy
Director, 10% Owner
VANI Dec 15, 2025
Avg Cost/Share
$1.19
Shares
1,737,765
Total Value
$1,983,333.94
Owned After
24,561,793
Williams Gregg
Buy
Director, 10% Owner
VANI Nov 15, 2025
Avg Cost/Share
$1.19
Shares
1,737,764
Total Value
$1,983,332.68
Owned After
24,561,793
Williams Gregg
Buy
Director, 10% Owner
VANI Oct 27, 2025
Avg Cost/Share
$1.62
Shares
3,703,703
Total Value
$5,999,998.86
Owned After
24,561,793
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mendelsohn Aaron | VANI | Director | Dec 29, 2025 | Buy | $1.23 | 20,000 | $24,600.00 | 188,170 | |
| Williams Gregg | VANI | Director, 10% Owner | Dec 15, 2025 | Buy | $1.19 | 1,737,765 | $1,983,333.94 | 24,561,793 | |
| Williams Gregg | VANI | Director, 10% Owner | Nov 15, 2025 | Buy | $1.19 | 1,737,764 | $1,983,332.68 | 24,561,793 | |
| Williams Gregg | VANI | Director, 10% Owner | Oct 27, 2025 | Buy | $1.62 | 3,703,703 | $5,999,998.86 | 24,561,793 |
Latest Vivani Medical Inc. (DE) News
VANI Breaking Stock News: Dive into VANI Ticker-Specific Updates for Smart Investing
ACCESS Newswire
MassRobotics Announces 5th Cohort of Healthcare Robotics Startup Catalyst Program
📈
AI Sentiment
Highly Positive
9/10
ACCESS Newswire
Ecoldbrew Wins Best of CES, Redefining Cold Brew Coffee in Minutes
📈
AI Sentiment
Highly Positive
9/10
ACCESS Newswire
Smarter Reporting, Clearer Decisions: Bitrix24 BI Builder Simplifies Workflows
📈
AI Sentiment
Highly Positive
8/10
ACCESS Newswire
Guiding Stars: Protein Pressure: Separating Fact From Hype
âž–
AI Sentiment
Neutral
5/10
GuruFocus.com
TSMC Earnings Beat Lifts Futures as Oil and Silver Pull Back
📈
AI Sentiment
Highly Positive
8/10
Compare VANI vs Leading Stocks
See how VANI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VANI Vivani Medical Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.